Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis

• Main Authors: Peter A. Lio (Author), April Armstrong (Author), Jan Gutermuth (Author), Audrey Nosbaum (Author), Howard Sofen (Author), Esther Garcia Gil (Author), Marta Casillas (Author), Sherry Chen (Author), Luna Sun (Author), Evangeline Pierce (Author), Hany Elmaraghy (Author), Zach Dawson (Author), Tiago Torres (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient's quality of life (QoL) and mental health. Here, we assess the impact of lebrikizumab on QoL and mental health after 16 weeks of treatment in pati...